JPWO2020089819A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020089819A5
JPWO2020089819A5 JP2021518633A JP2021518633A JPWO2020089819A5 JP WO2020089819 A5 JPWO2020089819 A5 JP WO2020089819A5 JP 2021518633 A JP2021518633 A JP 2021518633A JP 2021518633 A JP2021518633 A JP 2021518633A JP WO2020089819 A5 JPWO2020089819 A5 JP WO2020089819A5
Authority
JP
Japan
Prior art keywords
substance
alpha
kit
agent
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518633A
Other languages
Japanese (ja)
Other versions
JP2022505022A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059331 external-priority patent/WO2020089819A1/en
Publication of JP2022505022A publication Critical patent/JP2022505022A/en
Publication of JPWO2020089819A5 publication Critical patent/JPWO2020089819A5/ja
Pending legal-status Critical Current

Links

Claims (21)

対象の身体に少なくとも部分的に導入され、その上にアルファ放出原子が取り付けられている少なくとも１つの線源と；
細胞内病原体に対する細胞質センサーを活性化する少なくとも１つの物質と；そして
前記少なくとも１つの線源と前記少なくとも１つの物質を含む無菌パッケージと；
を有することを特徴とする、患者の治療のためのキット。 at least one radiation source at least partially introduced into a subject's body and having alpha-emitting atoms attached thereon;
at least one substance that activates a cytoplasmic sensor for intracellular pathogens; and a sterile package containing said at least one radiation source and said at least one substance;
A kit for treating a patient, comprising: アルファ放出原子またはそれらの娘放射性核種の線源からの制御可能な放出を可能にする態様で、アルファ放出原子が線源に取り付けられている、ことを特徴とする請求項１に記載のキット。 2. The kit of claim 1 , wherein the alpha-emitting atoms are attached to the source in a manner that allows controllable release from the source of alpha-emitting atoms or their daughter radionuclides. 前記アルファ放出原子はラジウム原子を含む、ことを特徴とする請求項１に記載のキット。 2. The kit of claim 1 , wherein said alpha emitting atoms comprise radium atoms. 前記少なくとも１つの物質がＤＮＡメチルトランスフェラーゼ（ＤＮＭＴ）阻害剤を含む、ことを特徴とする請求項１～３のいずれかに記載のキット。 Kit according to any one of claims 1 to 3 , characterized in that said at least one substance comprises a DNA methyltransferase (DNMT) inhibitor. 前記ＤＮＡメチルトランスフェラーゼ（ＤＮＭＴ）阻害剤がデシタビンを含む、ことを特徴とする請求項４に記載のキット。 5. The kit of claim 4 , wherein said DNA methyltransferase (DNMT) inhibitor comprises decitabine. 前記少なくとも１つの物質が、病原体模倣物の細胞質送達に適した送達剤を伴う病原体模倣物をさらに含む、ことを特徴とする請求項４に記載のキット。 5. The kit of claim 4 , wherein said at least one substance further comprises a pathogen mimetic with a delivery agent suitable for cytoplasmic delivery of the pathogen mimetic. 前記少なくとも１つの物質が、病原体模倣物の細胞質送達に適した送達剤を伴う病原体模倣物を含む、請求項１～３のいずれかに記載のキット。 4. The kit of any of claims 1-3 , wherein said at least one substance comprises a pathogen mimetic with a delivery agent suitable for cytoplasmic delivery of the pathogen mimetic. アルファ放射体放射線療法によって誘発される加速された組織修復に対抗する支持的治療薬をさらに前記無菌パッケージに含む、ことを特徴とする請求項１～３のいずれかに記載のキット。 The kit of any of claims 1-3 , further comprising in the sterile package a supportive therapeutic agent against accelerated tissue repair induced by alpha-emitter radiotherapy. 前記支持的治療薬が、炎症をダウンレギュレートする薬剤を含む、ことを特徴とする請求項８に記載のキット。 9. The kit of claim 8 , wherein said supportive therapeutic agent comprises an agent that downregulates inflammation. 患者の腫瘍の処置のための医薬品として使用される、細胞内病原体に対する細胞質センサーを活性化する物質であって、前記医薬品の投与パターンは、１回以上のセッションで治療的に有効な量の前記物質を前記腫瘍に投与するステップと；そして前記物質の投与から２週間以内に腫瘍内アルファ放射体放射線療法で前記腫瘍を処置するステップと；を有する、A substance that activates a cytosolic sensor against intracellular pathogens for use as a pharmaceutical agent for the treatment of a tumor in a patient, wherein the dosage pattern of said pharmaceutical agent is a therapeutically effective amount of said agent in one or more sessions. administering an agent to said tumor; and treating said tumor with intratumoral alpha-emitter radiotherapy within two weeks of administration of said agent;
ことを特徴とする、医薬品として使用される物質。A substance used as a drug, characterized by: 前記物質は、病原体模倣物の細胞質送達に適した送達剤を備える前記病原体模倣物を有する、ことを特徴とする請求項１０に記載の、医薬品として使用される物質。11. A substance for use as a pharmaceutical product according to claim 10, characterized in that said substance comprises said pathogen mimetic with a delivery agent suitable for cytoplasmic delivery of said pathogen mimetic. 前記物質はウイルス模倣物を有する、ことを特徴とする請求項１０または１１に記載の、医薬品として使用される物質。12. Substance for use as a medicament according to claim 10 or 11, characterized in that said substance has a viral mimetic. 前記物質はポリエチレンイミン（ＰＥＩ）を備えるｐｏｌｙＩＣを有する、ことを特徴とする請求項１０－１２のいずれかに記載の、医薬品として使用される物質。A substance for use as a medicament according to any of claims 10-12, characterized in that said substance has a polyIC with polyethylenimine (PEI). 前記物質はｐｏｌｙＩＣＬＣを有する、ことを特徴とする請求項１０－１２のいずれかに記載の、医薬品として使用される物質。A substance for use as a medicament according to any of claims 10-12, characterized in that said substance has polyICLC. 前記物質は腫瘍溶解性ウイルスを有する、ことを特徴とする請求項１０に記載の、医薬品として使用される物質。11. Substance for use as a medicament according to claim 10, characterized in that said substance carries an oncolytic virus. 前記物質はＤＮＡメチルトランスフェラーゼ（ＤＮＭＴ）阻害剤を有する、ことを特徴とする請求項１０に記載の、医薬品として使用される物質。11. Substance for use as a medicament according to claim 10, characterized in that said substance has a DNA methyltransferase (DNMT) inhibitor. 前記物質はデシタビンを有する、ことを特徴とする請求項１６に記載の医薬品として使用される物質。17. Substance for use as a medicament according to claim 16, characterized in that said substance comprises decitabine. 前記医薬品の投与パターンはさらに、チェックポイント阻害のための支持的治療薬を投与するステップを有する、ことを特徴とする請求項１０－１７のいずれかに記載の、医薬品として使用される物質。A substance for use as a medicament according to any of claims 10-17, characterized in that said pharmaceutical dosing pattern further comprises administering a supportive therapeutic agent for checkpoint inhibition. 前記支持的治療薬はチェックポイント遮断薬を有する、ことを特徴とする請求項１８に記載の、医薬品として使用される物質。19. Substance for use as a pharmaceutical product according to claim 18, characterized in that said supportive therapeutic agents comprise checkpoint blockers. 前記腫瘍内アルファ放射体放射線療法はラジウム原子を担持する線源により提供される、ことを特徴とする請求項１０－１９のいずれかに記載の、医薬品として使用される物質。A substance for use as a medicament according to any of claims 10-19, characterized in that said intratumoral alpha-emitter radiotherapy is provided by a source carrying radium atoms. 前記腫瘍内アルファ放射体放射線療法は、アルファ放出原子またはそれらの娘放射性核種の線源からの制御可能な放出を可能にする態様で搭載される、アルファ放出原子を担持する線源により提供される、ことを特徴とする請求項１０－２０のいずれかに記載の、医薬品として使用される物質。Said intratumoral alpha-emitter radiotherapy is provided by a source carrying alpha-emitting atoms mounted in a manner that allows controllable release from the source of alpha-emitting atoms or their daughter radionuclides. A substance for use as a medicament according to any one of claims 10 to 20, characterized in that .
JP2021518633A 2018-11-01 2019-10-31 Activation of cytoplasmic plasma sensor for intracellular alpha radiator radiation and intracellular pathogens Pending JP2022505022A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753930P 2018-11-01 2018-11-01
US62/753,930 2018-11-01
PCT/IB2019/059331 WO2020089819A1 (en) 2018-11-01 2019-10-31 Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen

Publications (2)

Publication Number Publication Date
JP2022505022A JP2022505022A (en) 2022-01-14
JPWO2020089819A5 true JPWO2020089819A5 (en) 2022-10-19

Family

ID=70464034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518633A Pending JP2022505022A (en) 2018-11-01 2019-10-31 Activation of cytoplasmic plasma sensor for intracellular alpha radiator radiation and intracellular pathogens

Country Status (9)

Country Link
US (1) US20210379096A1 (en)
EP (1) EP3873598A4 (en)
JP (1) JP2022505022A (en)
KR (1) KR20210087949A (en)
CN (2) CN112912137B (en)
AU (2) AU2019370892B2 (en)
CA (1) CA3114299A1 (en)
SG (1) SG11202102627PA (en)
WO (1) WO2020089819A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9821174B1 (en) 2015-02-06 2017-11-21 Gammatile Llc Radioactive implant planning system and placement guide system
US10888710B1 (en) 2016-11-29 2021-01-12 Gt Medical Technologies, Inc. Transparent loading apparatus
CN116171152A (en) * 2020-09-15 2023-05-26 昂科因凡特公司 Prepared radium-224 and offspring combined DNA repair inhibitor for radionuclide therapy
JP2024503995A (en) 2020-12-16 2024-01-30 アルファ タウ メディカル リミテッド Diffuse alpha emitter radiotherapy with enhanced beta radiation therapy
CN113230400A (en) * 2021-03-11 2021-08-10 上海交通大学 Gold nanocluster radiotherapy sensitization assembly based on epigenetic regulation and control as well as preparation and application thereof
US12064643B2 (en) 2021-06-10 2024-08-20 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for breast cancer
US12042668B2 (en) 2021-06-10 2024-07-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for squamous cell carcinoma
US20220395701A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for pancreatic cancer
US12070621B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for pancreatic cancer
US12076582B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for colorectal cancer
US12076581B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
US11964168B2 (en) 2021-06-10 2024-04-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for prostate cancer
US12070620B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Activity levels for diffusing alpha-emitter radiation therapy
US20220395703A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Activity levels for diffusing alpha-emitter radiation therapy
US12076583B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for melanoma
US20220395702A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
US12053644B2 (en) 2021-12-30 2024-08-06 Gt Medical Technologies, Inc. Radiation shielding apparatus for implantable radioactive seeds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248057B1 (en) 1998-07-28 2001-06-19 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
EP1644049B1 (en) 2003-04-30 2007-09-26 Ramot at Tel Aviv University Ltd. Method and device for radiotherapy
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
SI1909855T1 (en) 2005-07-26 2018-06-29 Alpha Tau Medical Ltd. A radioactive surface source and a method for producing the same
US20090088401A1 (en) 2007-09-27 2009-04-02 Andres Salazar In-situ cancer autovaccination with intratumoral stabilized dsRNA viral mimic
US20090234628A1 (en) * 2008-03-14 2009-09-17 Siemens Medical Solutions Usa, Inc. Prediction of complete response given treatment data
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
US8821364B2 (en) 2008-09-02 2014-09-02 Battelle Memorial Institute Brachytherapy seed with fast dissolving matrix for optimal delivery of radionuclides to cancer tissue
WO2011024172A2 (en) 2009-08-27 2011-03-03 Technion Research & Development Foundation Ltd. Liposomal compositions and uses of same
CA2787260A1 (en) * 2010-01-18 2011-07-21 Zhi-Min Yuan Methods and compositions for nanoparticle-mediated cancer cell-targeted delivery
WO2011161075A1 (en) * 2010-06-22 2011-12-29 Dna Therapeutics Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
US10421971B2 (en) * 2014-01-15 2019-09-24 The University Of Chicago Anti-tumor therapy
EP4245376A3 (en) * 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
US20180214583A1 (en) * 2015-08-12 2018-08-02 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
CN105031648A (en) * 2015-08-25 2015-11-11 徐州医学院 Novel targeting nanoparticle as well as preparation method and application thereof
CN112294757B (en) * 2015-11-17 2024-02-13 亮点医疗有限责任公司 Pharmaceutical composition comprising particles comprising a complex of a double stranded polyribonucleotide and a polyalkyleneimine
WO2017173101A1 (en) * 2016-03-30 2017-10-05 Virginia Commonwealth University Combination therapy for neuroblastoma using mda-7/il-24 with therapeutic agents
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
JP7274214B2 (en) * 2016-08-02 2023-05-16 プレジデント アンド フェローズ オブ ハーバード カレッジ Biomaterials for modulating immune responses
CA3033542A1 (en) * 2016-08-30 2018-03-08 Dana-Farber Cancer Institute, Inc. Compositions and uses of biomaterials and activators of innate immunity
WO2018042411A1 (en) 2016-09-04 2018-03-08 Alex Levitzki Management And Holdings, Ltd. Chimeric proteins for targeting dsrna
EP3321362A1 (en) * 2016-11-10 2018-05-16 Centre Leon Berard Tlr3 agonist for use for inducing apoptosis in senescent cancer cells
WO2018183885A1 (en) * 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
CA3057558A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy
RU2763750C2 (en) 2017-05-11 2022-01-10 Альфа Тау Медикал Лтд. Polymer coatings for brachytherapy devices
US11851712B2 (en) * 2018-03-06 2023-12-26 Board Of Regents, The University Of Texas System Replication stress response biomarkers for immunotherapy response
KR20200139722A (en) 2018-04-02 2020-12-14 알파 타우 메디컬 리미티드 Controlled release of radionuclides
CN112770781A (en) * 2018-09-26 2021-05-07 阿森迪斯药物股份有限公司 Novel hydrogel conjugates

Similar Documents

Publication Publication Date Title
JPWO2020089819A5 (en)
Fekrazad Photobiomodulation and antiviral photodynamic therapy as a possible novel approach in COVID-19 management
Smee et al. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir
CY1120445T1 (en) COMBINATIONS AND METHODS OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY
JP2020523359A5 (en)
RU2003131876A (en) COMPOSITIONS OF N-ACETYLCYSTEINE AND METHODS OF TREATMENT AND PREVENTION OF TOXICITY OF MEDICINES
ES2570401T3 (en) Methods of treatment using single doses of oritavancin
JP2020117553A5 (en)
EP3456359B1 (en) Neutron capture therapy composition formed using ion implantation
BR112015030881A2 (en) "DOSAGE SCHEME AND FORMULATIONS FOR TYPE B ADENOVIRUS"
Jayant et al. Nanotechnology for the treatment of NeuroAIDS
Liau et al. The winner of the contest to eradicate cancer stem cells wins the contest of cancer therapies: The winner is cell differentiation agent formulations
JP2017515847A5 (en)
Gopisankar et al. Oncolytic virotherapy–A novel strategy for cancer therapy
Guo The impact of hypoxia on oncolytic virotherapy
JP2013525422A5 (en)
EP3525783B1 (en) Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine
Alfieri et al. The relationship between the time of fractionated and single doses of radiation and hyperthermia on the sensitization of an in vivo mouse tumor
JP2020501589A5 (en)
Cividalli et al. Hyperthermia and paclitaxel-epirubicin chemotherapy: enhanced cytotoxic effect in a murine mammary adenocarcinoma
PT1251850E (en) USE OF A PREPARATION OF COMBINATION IN CANCER THERAPY
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
Rezaee et al. Radiosensitizing effect of electrochemotherapy: a systematic review of protocols and efficiency
Bakhshi et al. Efficacy of bioxtra spray and mouthwash in patients with radiation-induced xerostomia: a randomized clinical trial
Liau et al. Royal family’s cancer diagnoses offer a supreme authority to rectify cancer therapies to save cancer patients